Citations

Clear

3030 citation(s) found for "Susan, M".

Neonatal circumcision in severe haemophilia: a survey of paediatric haematologists at United States Hemophilia Treatment Centers
Kearney, Susan , Sharathkumar, Anjali , Rodriguez, Vilmarie , Chitlur, Meera , Valentino, Leonard A. , Boggio, Lisa , Valentino, Leonard A. , Gill, Michael John

Mayo Clinic

Haemophilia | December 5, 2014 | Volume: 21 | Issue: 1 | Pages: 52-57

10.1111/hae.12528 | PMID 25472876 Get It

SummaryNeonatal circumcision in patients with severe haemophilia has not been well studied. We performed a survey of paediatric haematologists from Hemophilia Treatment Centers (HTC) across the United States to better understand the attitudes toward and management of neonatal circumcision in haemophilia patients. Response rate to our survey was 40% (n = 64/159). Thirty‐eight percent of respondents (n = 24) said that they would allow this procedure in the newborn period but in many cases this was against medical advice. The most reported concern regarding neonatal circumcision in haemophilia patients was the risk of development of an inhibitor (n = 25; 39%) followed by the concern for bleeding (n = 22; 34%) and issues related to vascular access in the neonate (n = 11; 17%). All respondents recommended at least one preprocedure dose of factor replacement. Twenty‐two percent (n = 14) of respondents did not use more than one dose of factor replacement but 32% (n = 21) used 1–2 postoperative doses. The remainder of paediatric haematologists surveyed recommended between 3–5 (16%; n = 10) and 6–10 (3%, n = 2) additional days postoperatively. There was wide variation in both techniques of circumcision as well as adjuvant haemostatic agents used. Only 22% of respondents said that they had an established protocol for management of circumcision in the newborn haemophilia patient. These survey results highlight the need for evidence‐based guidelines regarding the optimal management of circumcision in neonates with severe haemophilia.
Circulating Sex Hormones and Terminal Duct Lobular Unit Involution of the Normal Breast
Khodr, Zeina G. , Brinton, Louise A. , Patel, Deesha A. , Linville, Laura , Papathomas, Daphne, Clare, Susan E. , Visscher, Daniel W., Mies, Carolyn, Hewitt, Stephen M. , Storniolo, Anna Maria , Rosebrock, Adrian , Caban, Jesus J., Figueroa, Jonine D. , Sherman, Mark E. , Pfeiffer, Ruth M. , Gierach, Gretchen L. , Falk, Roni T. , Figueroa, Jonine D

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 3, 2014 | Volume: 23 | Issue: 12 | Pages: 2765-2773

10.1158/1055-9965.epi-14-0667 | PMID 25472681 Get It

Abstract Background: Terminal duct lobular units (TDLU) are the predominant source of breast cancers. Lesser degrees of age-related TDLU involution have been associated with increased breast cancer risk, but factors that influence involution are largely unknown. We assessed whether circulating hormones, implicated in breast cancer risk, are associated with levels of TDLU involution using data from the Susan G. Komen Tissue Bank (KTB) at the Indiana University Simon Cancer Center (2009–2011). Methods: We evaluated three highly reproducible measures of TDLU involution, using normal breast tissue samples from the KTB (n = 390): TDLU counts, median TDLU span, and median acini counts per TDLU. RRs (for continuous measures), ORs (for categorical measures), 95% confidence intervals (95% CI), and Ptrends were calculated to assess the association between tertiles of estradiol, testosterone, sex hormone–binding globulin (SHBG), progesterone, and prolactin with TDLU measures. All models were stratified by menopausal status and adjusted for confounders. Results: Among premenopausal women, higher prolactin levels were associated with higher TDLU counts (RRT3vsT1:1.18; 95% CI: 1.07–1.31; Ptrend = 0.0005), but higher progesterone was associated with lower TDLU counts (RRT3vsT1: 0.80; 95% CI: 0.72–0.89; Ptrend < 0.0001). Among postmenopausal women, higher levels of estradiol (RRT3vsT1:1.61; 95% CI: 1.32–1.97; Ptrend < 0.0001) and testosterone (RRT3vsT1: 1.32; 95% CI: 1.09–1.59; Ptrend = 0.0043) were associated with higher TDLU counts. Conclusions: These data suggest that select hormones may influence breast cancer risk potentially through delaying TDLU involution. Impact: Increased understanding of the relationship between circulating markers and TDLU involution may offer new insights into breast carcinogenesis. Cancer Epidemiol Biomarkers Prev; 23(12); 2765–73. ©2014 AACR.
Establishment of the Cancer Prevention Study II Nutrition Cohort Colorectal Tissue Repository
Deka, Anusila , Cicek, Mine , Farris, Alton B. , Gaudet, Mia M. , Jacobs, Eric J. , Newton, Christina C. , Patel, Alpa V. , Thibodeau, Stephen N. , Tillmans, Lori S. , Gapstur, Susan M. , Tillmans, Lori, Campbell, Peter T. , Briggs, Peter , Teras, Lauren R. , Farris, Alton B

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 3, 2014 | Volume: 23 | Issue: 12 | Pages: 2694-2702

10.1158/1055-9965.epi-14-0541 | PMID 25472679 Get It

Abstract Background: To better understand colorectal cancer etiology and prognosis, archived surgical tissues were collected from Cancer Prevention Study II (CPS-II) Nutrition Cohort participants who were diagnosed with colorectal cancer. Herein, the methodology for this collection is described to help inform other efforts to collect tissues. Methods: The main components to accruing tissue were: (i) obtaining consent from participants or next-of-kin; (ii) contacting hospitals to request materials; and (iii) pathology review and laboratory processing. Results: In CPS-II, we identified 3,643 participants diagnosed with colorectal cancer between 1992/1993 and 2009. Of these, tissue could not be sought from cases verified through state cancer registry linkage (N = 1,622), because of insufficient information on tissue location. We sought tissue from the 2,021 cases verified using medical records, and received tissue from 882. When hospitals were contacted within 10 years of diagnosis, we received 87% of tissue materials; beyond that 10-year mark, we received 32%. Compared with the 2,761 colorectal cancer cases without tissue, the 882 cases with tissue were more likely to be alive, diagnosed more recently during follow-up, and had less-advanced staged disease. Cases with and without tissues were similar with respect to age at diagnosis, smoking, body mass index, physical activity, and other epidemiologic factors. Conclusions: Some of the most important elements in forming a tissue repository included having the cases' hospital contact and surgical accession information as well as contacting patients/next-of-kin and hospitals within 10 years of surgery. Impact: This tissue repository will serve as an important resource for colorectal cancer studies. See all the articles in this CEBP Focus section, “Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology.” Cancer Epidemiol Biomarkers Prev; 23(12); 2694–702. ©2014 AACR.
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Fouladi, Maryam , Perentesis, John P. , Wagner, Lars M. , Vinks, Alexander A. , Ahern, Charlotte H., Mercer, Carol A. , Krueger, Darcy A. , Houghton, Peter J. , Doyle, L. Austin, Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Thomas, George , Chen, Helen

Mayo Clinic

Clinical Cancer Research | December 2, 2014 | Volume: 21 | Issue: 7 | Pages: 1558-1565

10.1158/1078-0432.ccr-14-0595 | PMID 25467181 Get It

Abstract Purpose: To determine the MTD, dose-limiting toxicities (DLT), pharmacokinetics, and biologic effects of cixutumumab administered in combination with temsirolimus to children with refractory solid tumors. Experimental Design: Cixutumumab and temsirolimus were administered intravenously once every 7 days in 28-day cycles. Pharmacokinetic and biology studies, including assessment of mTOR downstream targets in peripheral blood mononuclear cells, were performed during the first cycle. Results: Thirty-nine patients, median age 11.8 years (range, 1–21.5), with recurrent solid or central nervous system tumors were enrolled, of whom 33 were fully assessable for toxicity. There were four dose levels, which included two dose reductions and a subsequent intermediated dose escalation: (i) IMC-A12 6 mg/kg, temsirolimus 15 mg/m2; (ii) IMC-A12 6 mg/kg, temsirolimus 10 mg/m2; (iii) IMC-A12 4 mg/kg, temsirolimus 8 mg/m2; and (iv) IMC-A12 6 mg/kg, temsirolimus 8 mg/m2. Mucositis was the predominant DLT. Other DLTs included hypercholesterolemia, fatigue, thrombocytopenia, and increased alanine aminotransferase. Target inhibition (decreased S6K1 and PAkt) in peripheral blood mononuclear cells was noted at all dose levels. Marked interpatient variability in temsirolimus pharmacokinetic parameters was noted. At 8 mg/m2, the median temsirolimus AUC was 2,946 ng • h/mL (range, 937–5,536) with a median sirolimus AUC of 767 ng • h/mL (range, 245–3,675). Conclusions: The recommended pediatric phase II doses for the combination of cixutumumab and temsirolimus are 6 mg/kg and 8 mg/m2, respectively. Clin Cancer Res; 21(7); 1558–65. ©2014 AACR.
Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Hart, Steven N. , Sharma, Priyanka , Miron, Penelope , Olswold, Curtis, Slettedahl, Seth W. , Hallberg, Emily, Guidugli, Lucia, Davila, Jaime , Beckmann, Matthias W. , Janni, Wolfgang , Rack, Brigitte , Ekici, Arif B. , Slamon, Dennis J. , Konstantopoulou, Irene , Vratimos, Athanassios, Fountzilas, George , Pelttari, Liisa M. , Tapper, William , Durcan, Lorraine , Cross, Simon S. , Pilarski, Robert , Klemp, Jennifer R. , Cox, Angela , Brauch, Hiltrud , Yannoukakos, Drakoulis , Slager, Susan L., Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A. , Eccles, Diana , Wang, Xianshu , Slettedahl, Seth, Davila, Jaime I, Tapper, William J, Shapiro, Charles L. , Klemp, Jennifer, Garber, Judy, Ambrosone, Christine, Couch, Fergus J. , Toland, Amanda Ewart , Olson, Janet E. , Godwin, Andrew K. , Pankratz, V. Shane , Fostira, Florentia , Yao, Song , Garber, Judy E. , Ambrosone, Christine B. , Nevanlinna, Heli , Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A , Pelttari, L M , Eccles, Diana , Konstantopoulou, Irene , Slettedahl, Seth W , Hart, Steven N , Cox, Angela , Ekici, Arif B , Davila, Jaime I , Yannoukakos, Drakoulis , Sharma, Priyanka , Brauch, Hiltrud

Mayo Clinic

Journal of Clinical Oncology | December 2, 2014 | Volume: 33 | Issue: 4 | Pages: 304-311

10.1200/jco.2014.57.1414 | PMID 25452441 Get It

Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing of patients. We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-negative breast cancer (TNBC) unselected for family history of breast or ovarian cancer to determine the utility of germline genetic testing for those with TNBC. Patients and Methods Patients with TNBC (N = 1,824) unselected for family history of breast or ovarian cancer were recruited through 12 studies, and germline DNA was sequenced to identify mutations. Results Deleterious mutations were identified in 14.6% of all patients. Of these, 11.2% had mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes. Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority observed in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%). Patients with TNBC with mutations were diagnosed at an earlier age (P < .001) and had higher-grade tumors (P = .01) than those without mutations. Conclusion Deleterious mutations in predisposition genes are present at high frequency in patients with TNBC unselected for family history of cancer. Mutation prevalence estimates suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2. Although mutations in other predisposition genes are observed among patients with TNBC, better cancer risk estimates are needed before these mutations are used for clinical risk assessment in relatives.
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
Correia, Cristina , Schneider, Paula A., Dai, Haiming , Church, Amy K., Novak, Anne J. , Feldman, Andrew L. , Wu, Xiaosheng , Ding, Husheng, Meng, X. Wei, Macon, William R. , Karp, Judith E. , Gore, Steven D. , Jelinek, Diane F., Nowakowski, Grzegorz S. , Doǧan, Ahmet , Maurer, Matthew J. , Cerhan, James R. , Slager, Susan L. , Habermann, Thomas M. , Kay, Neil E. , Witzig, Thomas E. , Kaufmann, Scott H. , Feldman, Andrew L , Correia, Cristina , Dai, Haiming

Mayo Clinic

Blood | December 1, 2014 | Volume: 125 | Issue: 4 | Pages: 658-667

10.1182/blood-2014-04-571786 | PMID 25452615 Get It

Key Points BCL2 mutations in FL correlate with activation-induced cytidine deaminase expression and frequently alter the amino acid sequence of the protein. Mutations in the BCL2 coding sequence at diagnosis are associated with shortened time to transformation and earlier death due to lymphoma.
Management of Vascular Risk Factors in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Voeks, Jenifer H. , Leimgruber, Pierre P., Mantese, Vito A., Timaran, Carlos H. , Chiu, David, Howard, Virginia J. , Hughes, Susan , Longbottom, Mary, Brott, Thomas G. , Meschia, James F. , Demaerschalk, Bart M. , Howard, Annie Green , Howard, Virginia J

Mayo Clinic

Journal of the American Heart Association | November 27, 2014 | Volume: 3 | Issue: 6 | Pages: No page available

10.1161/jaha.114.001180 | PMID 25428209 Get It

Background The Carotid Revascularization Endarterectomy Versus Stenting Trial ( CREST ) is a multicenter randomized trial of stenting versus endarterectomy in patients with symptomatic and asymptomatic carotid disease. This study assesses management of vascular risk factors. Methods and Results Management was provided by the patient's physician, with biannual monitoring results collected by the local site. Therapeutic targets were low‐density lipoprotein, cholesterol <100 mg/dL, systolic blood pressure <140 mm Hg, fasting blood glucose <126 mg/dL, and nonsmoking status. Optimal control was defined as achieving all 4 goals concurrently. Generalized estimating equations were used to compare risk factors at baseline with those observed in scheduled follow‐up visits for up to 48 months. In the analysis cohort of 2210, significant improvements in risk‐factor control were observed across risk factors for all follow‐up visits compared with baseline. At 48 months, achievement of the low‐density lipoprotein cholesterol goal improved from 59.1% to 73.6% ( P <0.001), achievement of the systolic blood pressure goal improved from 51.6% to 65.1% ( P <0.001), achievement of the glucose goal improved from 74.9% to 80.7% ( P =0.0101), and nonsmoking improved from 74.4% to 80.9% ( P <0.0001). The percentage with optimal risk‐factor control also improved significantly, from 16.7% to 36.2% ( P <0.001), but nearly 2 of 3 study participants did not achieve optimal control during the study. Conclusions Site‐based risk‐factor control improved significantly in the first 6 months and over the long term in CREST but was often suboptimal. Intensive medical management should be considered for future trials of carotid revascularization. Clinical Trial Registration URL: ClinicalTrials.gov. Unique identifier: NCT00004732.
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Mir, Muhammad A. , Maurer, Matthew J. , Ziesmer, Steven C., Macon, William R. , Link, Brian K. , Syrbu, Sergei , Friedberg, Jonathan W. , Press, Oliver W. , Novak, Anne J. , Ansell, Stephen M. , Slager, Susan L. , Habermann, Thomas M. , Witzig, Thomas E. , LeBlanc, Michael , Cerhan, James R. , Maurer, Matthew , Press, Oliver , Link, Brian K , Syrbu, Sergei

Mayo Clinic

Blood | November 24, 2014 | Volume: 125 | Issue: 6 | Pages: 992-998

10.1182/blood-2014-06-583369 | PMID 25422100 Get It

Key Points Elevated IL-2R, IL-1RA, and CXCL9 are associated with shorter event-free survival in newly diagnosed FL, treated with chemoimmunotherapy. Increased serum IL-12 and IL-1RA is associated with shorter event-free survival in patients who were observed or treated with rituximab alone.
Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?
Snyder, Peter J. , Kahle‐Wrobleski, Kristin, Brannan, Stephen K. , Schindler, Rachel, DeSanti, Susan, Ryan, J. Michael, Morrison, G. , Grundman, Michael, Chandler, Julie , Caselli, Richard J. , Isaac, Maria , Bain, Lisa J. , Carrillo, María C. , Miller, David S.

Mayo Clinic

Alzheimer's & Dementia | November 15, 2014 | Volume: 10 | Issue: 6 | Pages: 853-860

10.1016/j.jalz.2014.07.158 | PMID 25458309 Get It

AbstractSeveral lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The National Institute on Aging—Alzheimer's Association revised criteria for AD provided a framework for this new thinking. As a result of this growing understanding, several research efforts have launched or will be launching large secondary prevention trials in AD. These and other efforts have clearly demonstrated a need for better measures of cognitive and functional change in people with the earliest changes associated with AD. Recent draft guidance from the US Food and Drug Administration further elevated the importance of cognitive and functional assessments in early stage clinical trials by proposing that even in the pre‐symptomatic stages of the disease, approval will be contingent on demonstrating clinical meaningfulness. The Alzheimer's Association's Research Roundtable addressed these issues at its fall meeting October 28–29, 2013, in Washington, D.C. The focus of the discussion included the need for improved cognitive and functional outcome measures for clinical of participants with preclinical AD and those diagnosed with Mild Cognitive Impairment due to AD.
Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer
Reis, Francisco José Cândido dos , Song, Honglin , Goode, Ellen L. , Cunningham, Julie M. , Alsop, Kathryn , Dicks, Ed , Harrington, Patricia, Ramus, Susan J. , Fazio, Anna de , Mitchell, Gillian, Fereday, Sián , Bolton, Kelly L. , Gourley, Charlie , Michie, Caroline O. , Lester, Jenny, Walsh, Christine , Cass, Ilana, Olsson, Håkan , Gore, Martin, Benı́tez, Javier , García, María J. , Andrulis, Irene L. , Mulligan, Anna Marie , Glendon, Gord , Blanco, Ignacio , Lázaro, Conxi , Whittemore, Alice S. , McGuire, Valerie , Sieh, Weiva , Montagna, Marco , Alducci, Elisa, Sadetzki, Siegal , Chetrit, Angela , Kwong, Ava , Kjær, Susanne K. , Jensen, Allan , Høgdall, Estrid , Daly, Mary B., Greene, Mark H. , Mai, Phuong L., Loud, Jennifer T. , Moysich, Kirsten, Lambrechts, Diether , Ellis, Steve, Frost, Debra, Brenton, James D. , Easton, Douglas F. , Antoniou, Antonis C. , Chenevix‐Trench, Georgia , Gayther, Simon A. , Bowtell, David D.L. , DeFazio, Anna , Thorne, Heather , Lambrechts, Diether , Fridley, Brooke L. , Larson, Melissa C. , Karlan, Beth Y. , Neuhausen, Susan L. , Nussbaum, Robert L. , Mai, Phuong L., Toland, Amanda Ewart , Ellis, Steve, Tischkowitz, Marc D. , Pharoah, Paul D.P. , Lambrechts, Diether , Kjaer, Susanne K , Ramus, Susan J , Jensen, Allan , Brenton, James D , Moysich, Kirsten , Lambrechts, Diether , Sieh, Weiva , Benitez, Javier , Lazaro, Conxi , Montagna, Marco , Chenevix-Trench, Georgia , Høgdall, Estrid , Bolton, Kelly L , Bowtell, David D , Fereday, Sian , Alsop, Kathryn , Kwong, Ava

Mayo Clinic

Clinical Cancer Research | November 15, 2014 | Volume: 21 | Issue: 3 | Pages: 652-657

10.1158/1078-0432.ccr-14-2497 | PMID 25398451 Get It

Abstract Purpose: To analyze the effect of germline mutations in BRCA1 and BRCA2 on mortality in patients with ovarian cancer up to 10 years after diagnosis. Experimental Design: We used unpublished survival time data for 2,242 patients from two case–control studies and extended survival time data for 4,314 patients from previously reported studies. All participants had been screened for deleterious germline mutations in BRCA1 and BRCA2. Survival time was analyzed for the combined data using Cox proportional hazard models with BRCA1 and BRCA2 as time-varying covariates. Competing risks were analyzed using Fine and Gray model. Results: The combined 10-year overall survival rate was 30% [95% confidence interval (CI), 28%–31%] for non-carriers, 25% (95% CI, 22%–28%) for BRCA1 carriers, and 35% (95% CI, 30%–41%) for BRCA2 carriers. The HR for BRCA1 was 0.53 at time zero and increased over time becoming greater than one at 4.8 years. For BRCA2, the HR was 0.42 at time zero and increased over time (predicted to become greater than 1 at 10.5 years). The results were similar when restricted to 3,202 patients with high-grade serous tumors and to ovarian cancer–specific mortality. Conclusions: BRCA1/2 mutations are associated with better short-term survival, but this advantage decreases over time and in BRCA1 carriers is eventually reversed. This may have important implications for therapy of both primary and relapsed disease and for analysis of long-term survival in clinical trials of new agents, particularly those that are effective in BRCA1/2 mutation carriers. Clin Cancer Res; 21(3); 652–7. ©2014 AACR.